Investor100
8 years ago
Alder Presents Preclinical Data for ALD1613 at ENDO 2016
-ALD1613 Administration Reduces Plasma Corticosterone in Multiple Preclinical Models-
http://finance.yahoo.com/news/alder-presents-preclinical-data-ald1613-171500565.html
Key Points:
In vitro, ALD1613 inhibits ACTH-induced cortisol secretion in a mouse adrenal cell line.
ALD1613 administration in rats with artificially elevated ACTH and corticosterone levels resulted in a rapid and durable reduction of plasma corticosterone levels.
In non-human primates, ALD1613 demonstrated stable and durable reductions in plasma cortisol levels by >50%.
Randall C. Schatzman, Ph.D., President and Chief Executive Officer of Alder, said, βExisting therapeutic options for patients with congenital adrenal hyperplasia and Cushing's disease comprise treatments that provide limited disease control and involve significant side effects. We believe these limitations indicate a clear need for new therapies such as ALD1613, which targets ACTH to diminish the overproduction of cortisol. The data presented today demonstrate the capacity of ALD1613 to reduce corticosteroid levels in preclinical settings. We intend to use these studies as part of an IND filing that we plan to submit to the FDA in the second half of 2016.β
Investor 100
Investor100
8 years ago
Cramer @ ALDR
Looking forward to the Phase 3 results!
Buying the dip as well...
http://www.thestreet.com/story/13393479/1/jim-cramer-s-top-takeaways-alder-biopharmaceuticals-ensco.html?puc=yahoo&cm_ven=YAHOO
Alder BioPharmaceuticals (ALDR) : For his "Executive Decision" segment, Cramer spoke with Dr. Randall Schatzman, president and CEO of Alder BioPharmaceuticals, a stock that rallied over 11% in today's session but still remains 48% from its 2015 highs.
Schatzman said while it's been a wild week on Wall Street, the biopharmaceutical space has never been stronger. There is more innovation and more drugs being approved than ever.
When asked about his company's migraine treatment, which is currently in Phase III testing, Schatzman said the company believes it has identified and neutralized one of the primary factors that trigger migraines. So far, patients are responding well in the study. He said Alder has been successful using social media to spread the word to the 36 million migraine sufferers out there.
Schatzman was also upbeat on his company's arthritis drug, which will be entering Phase III trials soon.
Cramer said the best time to buy these stocks is when they're hated, not when they're loved.
Investor100
9 years ago
Migraine Statistics
In the U.S., more than 37 million people suffer from migraines. Some migraine studies estimate that 13 percent of adults in the U.S. population have migraines, and 2-3 million migraine suffers are chronic.
Almost 5 million in the U.S. experience at least one migraine attack per month, while more than 11 million people blame migraines for causing moderate to severe disability.
One study estimates the loss of productivity in the U.S. to be between $5.6 billion to $17.2 billion per year because of missed work. The average migraine sufferer misses two days of work per year. Some who suffer from persistent migraines work during a migraine attack, which they say lowers productivity. It is estimated that migraines are the reason for 36 million days of bed rest, plus 21.5 million days of restricted activity.
https://migraine.com/migraine-statistics/
Investor 100